
upgrad buy earlier
expect keytruda result
nsclc
result expect share ad keytruda label
upgrad buy hold rais pt
ep announc os data
keytruda chemo alimta carboplatin nsclc expect posit
data os/pf read-out came much earlier anticip
significantli longer os allow maintain first-
mover advantag nsclc file us/eu near-
term present full data upcom medic meet elcc/aacr
keytruda multipl data readout label expans support sale
vs street
data earlier expect upgrad
upgrad buy hold rais price target
ep mrk earlier expect
result phase mrk confirmatori
trial support keytruda buy alima pemetrex
statu comer interim analysi perform independ
data monitor committe recommend trial stop earlier due
keytruda chemo combo result post significantli longer os
standard care chemo combo plan share full
result upcom medic meet like elcc geneva switzerland
apr and/or chicago apr submit
data regulatori author expect file us/eu
respect expect posit data base
result click esmo postview assum
data readout delay per mrk call
remind downgrad octob click
compani ad overal surviv os co-primari endpoint
delay read-out pull keytruda eu nsclc file
acknowledg would potenti interim read-out
assum read-out earliest januari
read-out enabl maintain first-mov advantag
nsclc us file eu rais revenue/ep
vs street higher
hold buy
tr target
keytruda global sale lower out-year effect tax rate sales/ep cagr rise
vs street risk includ clinic regulatori commerci challeng
posit data put pressur bristol-my squibb buy
opdivo yervoy read-out patient expect click
result support keytruda uptak nsclc ex
provid detail data read-out howev note post-
esmo note click updat support keytruda first-mov advantag
nsclc ad confid object respons rate orr
esmo updat keytruda chemo continu almost doubl chemotherapi
alon vs howev median progression-fre surviv show
signific improv keytruda chemo arm read month vs month
chemotherapi hazard ratio around patient chemo arm discontinu
chemo treatment crossed-ov keytruda chemo arm median os reach
exhibit hazard ratio hr os updat analysi ci vs
previou month follow-up month follow-up term safeti
longer follow-up grade treatment-rel advers event trae broadli
rang keytruda chemo vs chemo
page
exhibit updat data keytruda chemo combo nsclc comer
page
confid monthsnot confid monthshazard ratioo hazard confid intervalsafetygrad lead previou result asco previou latest merck co inc
exhibit estim strh vs consensu us million except ep
page
page
page
gardasil cubicin product major total revenu total revenu merck co inc
exhibit incom statement us million expect earn per share
page
fye dec materi market research incom depreci total incom expens analysi gross market research oper pre-tax tax net chang gross market research oper pre-tax net metricspric merck co inc
exhibit consolid balanc sheet us million
page
fye dec short-term account prepaid expens tax current net properti plant intang loan payabl current portion lt account payabl accru incom tax dividend long-term defer incom tax non-current liabil paid-in comprehens co inc sharehold sharehold sharehold equiti merck co inc
exhibit statement us million
page
fye dec net compensaton asset impair incom dividend from tax work secur secur sale short-term issuanc lt long term treasuri stock exchang begin end merck co inc
merck co inc commit premier research-intens biopharmaceut
compani strategi discov develop provid innov product servic save
improv live around world innov medicin vaccin anim health product
gener us ex-u total revenu merck core area
focu oncolog diabet infecti diseas vaccin account
sale respect sever key brand product oncolog keytruda diabet januvia/
janumet/marizev japan virolog zepati drive growth addit growth opportun
immunolog women vaccin along grow biosimilar portfolio mrk anim
busi repres sale repres total sale
rate buy price target key global leader immuno-oncolog io
market flagship asset keytruda establish foundat io asset approv
favor clinic data multipl tumor type keytruda earlier expect posit result
non-smal cell lung cancer nsclc sourc upsid allow maintain first-mov
advantag import indic
one broadest clinic trial program trial
tumor type along combin trial sinc septemb keytruda approv
key indic us also grant number breakthrough therapi
design keytruda domin io market wall-of-data extend
mrk collabor astrazeneca lynparza parp deal
diabet mrk januvia/janumet franchis pressur type diabet market move
away toward newer effect agent like growth
mrk diabet franchis expect come inhibitor steglatro ertugliflozin
weekli marizev launch japan insulin conjug expect
launch
outsid oncolog anim health continu show strong growth think mrk
franchis consider competit pressur signific pressur come
virolog busi also see modest downward pressur mrk vaccin busi
zostavax face competit glaxosmithklin shingrix gardasil expect declin
us/eu due adopt two dose regimen vs previou three dose
model sales/ep cagr vs street
valuat risk
target price assum merck trade ep estim support
discount cash flow dcf model multipl ep group averag
think appropri given mrk leadership immuno-oncolog space
keytruda first-mov advantag nsclc
risk rate target price includ failur capit truda first-mov advantag
nsclc approv use januvia franchis see materi declin sale due rise
competit oral dpp-iv segment clinic regulatori risk keytruda
relebactam infect herp zoster valent pneumococc vaccin
global price risk invest risk relat biopharmaceut industri includ global price risk
payer polit risk clinic develop risk regulatori risk commerci risk legal
risk patent challeng
compani mention note
compani buy john bori
john bori herebi certifi view express research report accur reflect
person view subject compani secur also certifi
page
receiv direct indirect compens exchang express specif
recommend report
